Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia (CP-CML) significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment.
AstraZeneca’s KRAS deal with Yusen Jianheng; Abeona gets a PDUFA date
AstraZeneca partners with Chinese biotech: Yusen Jianheng Biopharmaceutical said last week that AstraZeneca will help develop and commercialize a preclinical small molecule that targets the
November 28, 2023